申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2019032631A1
公开(公告)日:2019-02-14
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is -OH or -OP(O)(OH)2; L1 is -CR3=N-O-CRaRa- or CRaR-O-N=CR3; L2 is a bond, -C(O)-, or S(O)2-;and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
公开的是Formula (I)的化合物:(I)或其盐,其中:X为CH或N;Y为CH或N;R1为-OH或-OP(O)(OH)2;L1为-CR3=N-O-CRaRa-或CRaR-O-N=CR3;L2为键,-C(O)-或S(O)2-;而R2、R3、Ra、m和n在此处有定义。还公开了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面非常有用,如自身免疫疾病和血管疾病。